Linnell J C, Bhatt H R
Vitamin B12 Unit, Chelsea and Westminster Hospital, London, UK.
Baillieres Clin Haematol. 1995 Sep;8(3):567-601. doi: 10.1016/s0950-3536(05)80221-5.
Cobalamins are essential biological compounds structurally related to haemoglobin and the cytochromes. Although the basic cobalamin molecule is only synthesized by micro-organisms, all mammalian cells can convert this into the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). AdoCbl is the major form in cellular tissues, where it is retained in the mitochondria. MeCbl predominates in blood plasma and certain other body fluids such as breast milk; in cells MeCbl is found in the cytosol. Inherited disorders of cobalamin metabolism are single gene defects, transmitted as recessive traits. They affect absorption, transport or intracellular metabolism of cobalamin. At least 12 different mutations are known, including defects or deficiencies of IF, IF-receptor and TCII, MM-CoA mutase and of the various reductases and synthases required for synthesis of AdoCbl and MeCbl. These have been designated cblA to cblG. Abnormalities are detectable by urine and plasma assays of methylmalonic acid and homocysteine, and plasma and erythrocyte analysis of cobalamin coenzymes, which can reveal deficiencies of MeCbl or AdoCbl. Fibroblast studies discriminate between closely similar defects. In man, AdoCbl is required in only two reactions: the catabolic isomerization of MM-CoA to succinyl-CoA and interconversion of alpha- and beta-leucine. MeCbl is required in the anabolic transmethylation of homocysteine to methionine. Intestinal absorption of cobalamin requires the glycoproteins TCI and IF from the stomach and IF-cobalamin receptors in the ileum. Cobalamin is transported to cells bound to a polypeptide, TCII, is captured by surface receptors and absorbed by endocytosis. The complex is then split in the lysosomes, cobalamin is released and the coenzymes are synthesized. In plasma, 80-90% of the cobalamin is bound to TCI, whose function is uncertain. Megaloblastic anaemia at birth or in the first few weeks of life is a rare but serious event. Myelopathy and developmental delay, with or without seizures may also occur without anaemia. If urine and light-protected blood samples are collected and sent to an appropriate metabolic unit, an inborn error of cobalamin metabolism, including TCII deficiency in which the serum B12 may be normal, can quickly be diagnosed. IF deficiency or Imerslund-Gräsbeck disease usually presents with signs of cobalamin deficiency within the first year of life and can be diagnosed by absorption studies. Current treatment involves dietary protein restriction and/or parenteral OHCbl and the prognosis is very variable. Since lack of MeCbl leads to depressed DNA synthesis affecting rapidly dividing cells in the brain and elsewhere, treatment with this coenzyme should be considered at the earliest stage in appropriate cases.(ABSTRACT TRUNCATED AT 400 WORDS)
钴胺素是与血红蛋白和细胞色素在结构上相关的必需生物化合物。虽然基本的钴胺素分子仅由微生物合成,但所有哺乳动物细胞都能将其转化为辅酶腺苷钴胺素(AdoCbl)和甲基钴胺素(MeCbl)。AdoCbl是细胞组织中的主要形式,它保留在线粒体中。MeCbl在血浆和某些其他体液如母乳中占主导地位;在细胞中,MeCbl存在于胞质溶胶中。钴胺素代谢的遗传性疾病是单基因缺陷,以隐性性状遗传。它们影响钴胺素的吸收、运输或细胞内代谢。已知至少有12种不同的突变,包括内因子(IF)、IF受体和转钴胺素II(TCII)、甲基丙二酰辅酶A(MM-CoA)变位酶以及合成AdoCbl和MeCbl所需的各种还原酶和合成酶的缺陷或缺乏。这些已被命名为cblA至cblG。通过尿液和血浆中甲基丙二酸和同型半胱氨酸的检测以及钴胺素辅酶的血浆和红细胞分析可以检测到异常,这可以揭示MeCbl或AdoCbl的缺乏。成纤维细胞研究可以区分非常相似的缺陷。在人类中,仅在两个反应中需要AdoCbl:MM-CoA分解代谢异构化为琥珀酰辅酶A以及α-和β-亮氨酸的相互转化。MeCbl在同型半胱氨酸合成蛋氨酸的合成性转甲基作用中是必需的。钴胺素的肠道吸收需要来自胃的糖蛋白转钴胺素I(TCI)和内因子以及回肠中的内因子-钴胺素受体。钴胺素与一种多肽TCII结合运输到细胞,被表面受体捕获并通过内吞作用吸收。然后复合物在溶酶体中分解,钴胺素释放出来并合成辅酶。在血浆中,80-90%的钴胺素与TCI结合,其功能尚不确定。出生时或生命的最初几周出现巨幼细胞贫血是一种罕见但严重的情况。也可能在没有贫血的情况下发生脊髓病和发育迟缓,伴有或不伴有癫痫发作。如果收集尿液和避光的血样并送到合适的代谢单位,钴胺素代谢的先天性缺陷,包括血清维生素B12可能正常的TCII缺乏,可迅速得到诊断。IF缺乏或Imerslund-Gräsbeck病通常在生命的第一年内出现钴胺素缺乏的体征,可通过吸收研究进行诊断。目前的治疗包括饮食蛋白质限制和/或肠外羟基钴胺素(OHCbl),预后差异很大。由于缺乏MeCbl会导致DNA合成受抑制,影响大脑和其他部位快速分裂的细胞,在适当的情况下应尽早考虑用这种辅酶进行治疗。(摘要截选至400字)